SEC Form 4 · accession 0001209191-15-011381
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Darryl S Baker
Officer — Chief Financial Officer
Period of report
Feb 6, 2015
Accepted (ET)
Feb 10, 2015 · 4:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Feb 6, 2015 | M | 15,000 | $2.36 | A | 34,377 | D | |
| Common StockF1 | Feb 6, 2015 | M | 6,248 | $7.26 | A | 40,625 | D | |
| Common StockF5 | Feb 6, 2015 | S | 15,000 | $52.252 | D | 25,625 | D | |
| Common StockF5 | Feb 6, 2015 | S | 6,248 | $52.252 | D | 19,377 | D | |
| Common StockF1 | Feb 9, 2015 | M | 8,752 | $7.26 | A | 28,129 | D | |
| Common StockF6 | Feb 9, 2015 | S | 8,752 | $52.184 | D | 19,377 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F8,F1,F7 | $2.36 | Feb 6, 2015 | M | 15,000 | D | — | Dec 26, 2022 | Common Stock | 15,000 | 60,000 | D |
| Stock Option (right to buy)F1,F9 | $7.26 | Feb 6, 2015 | M | 6,248 | D | — | May 13, 2023 | Common Stock | 6,248 | 118,752 | D |
| Stock Option (right to buy)F1,F9 | $7.26 | Feb 9, 2015 | M | 8,752 | D | — | May 13, 2023 | Common Stock | 8,752 | 110,000 | D |
Explanation of responses
- F1The exercise price reflects a 3-for-2 stock split effected by the Issuer on March 28, 2014.
- F2On March 28, 2014, the Issuer effected a 3-for-2 stock split, resulting in the reporting person's ownership of 10,000 additional shares of common stock.
- F3Includes 4,127 shares and 563 shares, respectively, acquired pursuant to the Issuer's ESPP on June 11, 2014 and December 11, 2014, respectively.
- F4The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan
- F5The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.0000 to $52.97 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.0000 to $52.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7The option vests in 36 equal monthly installments measured from the grant date of December 27, 2012 and will be fully vested and exercisable on December 27, 2015.
- F8On March 28, 2014, the Issuer effected a 3-for-2 stock split, resulting in the reporting person's ownership of 35,000 additonal options.
- F9The option vests in 48 equal monthly installments and will be fully vested and exercisable on May 14, 2017.